FDA Brief

Warning letters Drugs

FDA warning letter to

Foshan Yiying Hygiene Products Co., Ltd.

High riskIssued Oct 10, 2025Posted Oct 21, 2025Center for Drug Evaluation and Research (CDER)

Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

What happened

FDA did not inspect the plant; it reviewed records the company sent after FDA's February 10, 2025 request for records under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, which lets FDA demand records instead of visiting. The company's answers showed it did not test finished drug products for identity and strength of the active ingredient before release, did not do stability testing to support expiration dates, did not test incoming ingredients, and had not validated its manufacturing processes before shipping to the U.S. FDA placed all of the firm's drugs offered for import on Import Alert 66-40 on August 27, 2025.

What FDA found

  1. The company released drug batches without laboratory testing to confirm each batch met its specifications for identity and strength of the active ingredient.

    21 CFR 211.165(a)
  2. The company did no stability testing, so nothing shows the active ingredient stays within specifications through the labeled shelf life.

    21 CFR 211.137(a)
  3. The company did not test incoming ingredients to confirm their identity and did not verify the reliability of its suppliers' test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The company had no adequate written production and process control procedures and shipped to the U.S. before validating its manufacturing processes.

    21 CFR 211.100(a)
  5. The company stated it does not prepare batch production and control records for every batch, so it cannot show each batch was made the same way.

    21 CFR 211.188

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days describing what it has done and how it will prevent recurrence, or explain the delay and give a completion schedule. FDA also recommends hiring a qualified CGMP (current good manufacturing practice) consultant to audit the whole operation.

Who should pay attention

  • U.S. brands and distributors selling OTC drugs made by this firm
  • retailers and importers sourcing OTC drug products from China
  • suppliers and ingredient vendors whose certificates of analysis this site relied on

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk